ARCHIVES

ASCO Annual Meeting Attendance Tops 25,000, Continuing Fast Growth.

This article is from The Cancer Letter archive.

Vol. 27 No. 20 | May 18, 2001

Download PDF Visit The Full Archive

Related Articles

Herceptin Reduces Recurrence In Early HER2+ Breast Cancer

September 30, 2005

Litton Sells Clinical Labs, Planning to Join Recompetition For FCRF Contracts

July 12, 1985

ASCO Report Urges 5% Annual Increase For NIH.

December 8, 2006

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996

FDA Approves Merck’s Gardasil Vaccine To Prevent Cervical Cancer.

June 9, 2006